# ALK Abelló

> ALK Abelló is a VC fund in Hørsholm backing Biopharma and Health Care. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hørsholm, Denmark
- Total investments: 3
- Last investment: Jan 2011
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/alk-abello
- X (Twitter): http://twitter.com/ALK_net
- Website: http://www.alk-abello.com

ALK Abelló is a VC fund in Hørsholm focused on Biopharma and Health Care. ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. Since 1923 ALK has been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy.ALK is the world leader in allergy immunotherapy - a unique treatment of the cause ofallergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy immunotherapy products as injections, sublingual drops and sublingual tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes an adrenaline used to treat severe allergic reactions (anaphylactic shock).ALK invests annually approx. 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy. Research and development pipeline includes sublingual allergy immunoterapy tablets against ragweed, house dust mite and tree pollen allergy. ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialisation of tablets in Northern America and Japan.ALK has approx. 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B). In 2013 the turnover was more than DKK 2.2 billion (EURm 300).

## Contacts

5 contacts available for ALK Abelló. Shizune tracks 4 team members at ALK Abelló. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alk-abell?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 33% |
| Switzerland | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Flemming Pedersen | CFO, EVP Finance | 0 | — |
| Gry Agapitos | Senior Regulatory Affairs Manager | 0 | — |
| Henrik Jacobi | EVP, Research & Development | 0 | — |
| Søren Niegel | EVP, Commercial Operations | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Allegria Therapeutics | Allegria Therapeutics operates as a biotech company. | $5.1M | Seed | Dec 11, 2025 |  |
| DBV Technologies | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapythat aims to activate the immune system of patients through the skin. | $25.5M | Series C | Jan 05, 2011 |  |
| DBV Technologies | DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapythat aims to activate the immune system of patients through the skin. | $6.6M | Series B | Jan 22, 2009 |  |

3 of 3 investments shown.

## Co-investors
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [Alto Invest](https://shizune.co/investors/profile/alto-invest) — VC Fund, 1 deal together
- [Forty51 Ventures](https://shizune.co/investors/profile/forty51-ventures) — VC Fund, 1 deal together
- [HighLight Capital](https://shizune.co/investors/profile/highlight-capital) — VC Fund, 1 deal together
- [InnoBio Fund](https://shizune.co/investors/profile/innobio-fund) — VC Fund, 1 deal together
- [Lichtsteiner Foundation](https://shizune.co/investors/profile/lichtsteiner-foundation) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does ALK Abelló invest in?

ALK Abelló invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact ALK Abelló?

Public channels for ALK Abelló include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at ALK Abelló?

The team at ALK Abelló includes Flemming Pedersen (CFO, EVP Finance), Gry Agapitos (Senior Regulatory Affairs Manager) and Henrik Jacobi (EVP, Research & Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co